Abbott Laboratories Inc. said U.S. regulators had approved its rheumatoid arthritis treatment, Humira, which the company expects to become a blockbuster because it is easier to administer than rival treatments and may have safety advantages.
It will compete with Amgen Inc.'s treatment Enbrel and Johnson & Johnson's Remicade. All three products work by blocking a protein called tumor necrosis factor that causes inflammation that attacks the joints.
